Shares of Tiziana Life Sciences Plc (TLSA) are skyrocketing over 300% in pre-market today, after the company announced that it is expediting development of TZLS-501, a novel, fully human anti-interleukin-6 receptor (anti-IL6R) monoclonal antibody (mAb) for treatment of patients infected with coronavirus COVID-19 (SARS-CoV-2).
from RTT - Before the Bell https://ift.tt/3cNezS9
via IFTTT
No comments:
Post a Comment